Journal of Pharmaceutics & Drug Delivery Research ISSN: 2325-9604

Reach Us +1 209 730 0872
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Population Pharmacokinetics of Lixisenatide, a Once-Daily Human Glucagon-Like Peptide-1 Receptor Agonist, in Healthy Subjects and in Patients with Type 2 Diabetes

Population Pharmacokinetics of Lixisenatide, a Once- Daily Human Glucagon-Like Peptide-1 Receptor Agonist, in Healthy Subjects and in Patients with Type 2 Diabetes

Lixisenatide is a potent and selective glucagon-like peptide-1(GLP-1) receptor agonist developed for the treatment of type 2 diabetes (T2DM) with a subcutaneous once-daily regimen. The substance is currently under review for marketing authorization for the management of T2DM. In this study, the population pharmacokinetics in healthy volunteers and in adult T2DM patients was investigated.

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations